Foundation Medicine (NASDAQ:FMI)

CAPS Rating: 5 out of 5

FMI News and Commentary


How do you think FMI will perform against the market?

Add Stock to CAPS Watchlist

All Players

65 Outperform
2 Underperform

All-Star Players

25 Outperform
1 Underperform

Wall Street

0 Outperform
0 Underperform

Top FMI Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFInnovator (90.59)
Submitted September 03, 2014

Foundation Medicine runs high-speed genomic tests to profile individual patients, identify genetic abnormalities, and then recommend the best course of action for their treatment. I expect them to benefit from continued adoption of personalized… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

FMI VS S&P 500 (SPY)

Fools bullish on FMI are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about FMI.


Member Avatar iamtheschmitzer (64.85) Submitted: 6/7/2018 9:42:17 AM : Outperform Start Price: $100.35 FMI Score: +37.36

Emerging trend for genetic testing, early leader in cancer space - believe insurers will require testing for better outcomes


Member Avatar SaintCroix (99.22) Submitted: 12/7/2017 11:51:37 AM : Outperform Start Price: $37.80 FMI Score: +250.32

Competitor of NantHealth (NH). Their stock has tripled this year while NH has been killed.

Their test measures 300 genes, NH measures 22,000 genes.

FMI limits its test to the genes known to drive cancer growth.

NH might have better technology, but that doesn't always win (see Pac Bio vs. Illumina).

Roche invested $1 billion in FMI, which speaks volumes.

No profits yet, but sales are on fire.

1st quarter: $26 million
2nd quarter: $35 million
3rd quarter: $42 million

FDA just approved Foundation's test a few days ago, which should certainly help with early adaption.

From the press release...

"The first and only FDA-approved test of its kind for all solid tumors."

"Today approximately 50% of new cancer drugs in development are projected to have a companion biomarker."

Should be a major improvement in medical care. Analyze a person's genes, find the right drug for them. This company appears to be first mover and top dog. Probably a good idea to keep NH on your radar as well. I am very bullish.


Member Avatar volfan84 (91.82) Submitted: 11/13/2017 1:31:26 PM : Outperform Start Price: $50.15 FMI Score: +165.93

bulwnkl mentioned on Saul's board that a decision could be coming this quarter about reimbursement for Foundation's screening/treaments.


Find the members with the highest scoring picks in FMI.

Score Leader


majorguelth (63.74) Score: +698.42

The Score Leader is the player with the highest score across all their picks in FMI.

Member Name Member
Call Time
Score Commentary
majorguelth 63.74 1/14/2016 Outperform NS $16.19 +743.27% +44.85% +698.42 0 Comment
flounderuiuc 72.02 12/7/2015 Outperform 5Y $16.81 +712.17% +31.22% +680.94 0 Comment
coleman205 55.00 11/9/2015 Outperform 5Y $17.48 +681.04% +31.19% +649.85 0 Comment
SnoopyOne 87.05 3/14/2016 Outperform 5Y $18.24 +648.49% +35.43% +613.06 0 Comment
stereotyp72 77.31 1/24/2017 Outperform 5Y $18.60 +634.01% +21.27% +612.73 0 Comment
afurst < 20 10/9/2014 Outperform 1Y $19.18 +611.81% +39.85% +571.96 0 Comment
BRANTE 57.47 10/13/2014 Outperform 5Y $19.56 +597.98% +44.16% +553.82 0 Comment
pmadiraju 66.35 9/23/2014 Outperform 5Y $20.00 +582.62% +38.37% +544.26 0 Comment
misunderestimate < 20 5/19/2014 Outperform 5Y $20.37 +570.23% +46.28% +523.94 0 Comment
YMY 52.47 9/22/2014 Outperform 5Y $20.77 +557.32% +37.04% +520.28 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for FMI.

Featured Broker Partners